H
Hiroshi Nishihara
Researcher at Keio University
Publications - 677
Citations - 17201
Hiroshi Nishihara is an academic researcher from Keio University. The author has contributed to research in topics: Medicine & Terpyridine. The author has an hindex of 62, co-authored 616 publications receiving 14683 citations. Previous affiliations of Hiroshi Nishihara include Tokyo University of Science & Ochanomizu University.
Papers
More filters
Journal ArticleDOI
Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft
Che Yuan Hsu,Teruki Yanagi,Takuya Maeda,Hiroshi Nishihara,Kodai Miyamoto,H. Kitamura,Keiko Tokuchi,Hideyuki Ujiie +7 more
TL;DR: In this article , the effects of eribulin using cSCC cell lines and a novel cScc patient-derived xenograft (PDX) model were examined.
Journal ArticleDOI
Chemically Laminated 2D Bis(terpyridine)metal Polymer Films: Formation Mechanism at the Liquid-Liquid Interface and Redox Rectification.
TL;DR: In this paper , Nishihara et al. depicted the moment of the growth of the second layer at the liquid-liquid interface to form a heterolaminated film, which was later used in the development of the first layer.
Journal ArticleDOI
Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma
Ryohei Kufukihara,Nobuyuki Tanaka,Kimiharu Takamatsu,Naoya Niwa,Keishiro Fukumoto,Yota Yasumizu,Toshikazu Takeda,Kazuhiro Matsumoto,Shin-ya Morita,Takeo Kosaka,Eriko Aimono,Hiroshi Nishihara,Ryuichi Mizuno,Mototsugu Oya +13 more
TL;DR: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments and HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.
Journal ArticleDOI
ASO Author Reflections: Does Elevation of the Prognostic Factor Plasma Fibrinogen Level Reflect the Tumor Microenvironment at the Primary Site?
Shota Hoshino,Satoru Matsuda,Hirofumi Kawakubo,Shigeo Yamaguchi,Kohei Nakamura,Eriko Aimono,Kazuaki Matsui,Tomoyuki Irino,Kazumasa Fukuda,Rieko Nakamura,Hajime Okita,Hiroshi Nishihara,Y. Takeuchi,Yuko Kitagawa +13 more
TL;DR: The current study validated the prognostic impact of plasma FNG level in the larger cohort and identified that the high-FNG group had a sig-nificantly higher number of tumor-associated macrophages at the primary site.
Journal ArticleDOI
Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.
Sadakatsu Ikeda,Ryo Kudo,Yamato Yamashita,T. Kubo,Yukiko Mori,Yohei Harada,Hidekazu Shirota,Hideyuki Hayashi,Masayuki Kano,Yasuhiko Shimizu,Eri Ishibashi,Ukihide Tateishi,Akihiro Hirakawa,Hirotoshi Akita,Hisahiro Matsubara,Hiroshi Nishihara,Chikashi Ishioka,Naoko Sueoka-Aragane,Manabu Muto,Shinichi Toyooka +19 more
TL;DR: Combination therapy with trastuzumab and pertuzumabs was well tolerated and showed promising efficacy for the patients with HER2-amplified solid tumors determined by next-generation sequencing determined by NGS.